Selectivity of antidepressants: From the monoamine hypothesis of depression to the SSRI revolution and beyond

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 4, 2004, Pages 5-10

  Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENIC AMINE; CATECHOLAMINE; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

BIOGENIC MONOAMINES; CATECHOLAMINES; DEPRESSIVE DISORDER; HUMANS; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS;

EID: 2142822259     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Swazey JP, Reeds K. Today's Medicine, Tomorrow's Science: Essays on Paths of Discovery in the Biomedical Sciences. Washington, DC: US Dept Health, Education, and Welfare, Public Health Service, National Institutes of Health; 1978:120
2. von Euler US. Adrenergic neurotransnaitter functions: Nobel lecture. Available at: http://www.nobel.se/medicineflaureates/1970/ euler-lecture.pdf. Accessed May 13, 2003
3. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948:153:586-600
4. Vogt M. The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol (Lond) 1954;123:451-481
5. Rapport MM, Green AA, Page IH. Partial purification of the vasoconstrictor in beef serum. J Biol Chem 1948;174:735 741
6. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952:169:800-801
7. Twang EM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 1954;175: 157 161
8. Wooley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Natl Acad Sci 1954;40:223 231
9. Brodie EB, Shore PA, Silver SL. Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 1955;22:284 285
10. Axelrod J. Doing research in the intramural program of the National Institutes of Health. Perspect Biol Med 1986;29:S131-S137
11. Axelrod J, Tomchick R. Increased rate of metabolism of epinephrine and norepinephnne by symnpathomimetic amines. J Pharmacol Exp Ther 1960;130:367-369
12. Axelrod J. Catecholamine neurotransmitters, psychoactive dmgs, and biological clocks: the 1981 Harvey Cusbing oration. J Neurosurg 198 1;55:669-677
13. Carlsson A, Fuxe K, Ungerstedt U. The effect of iniipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 1968;20:150-151
14. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
15. Carlsson A, Jonason J, Lindqvist M, et al. Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res 1969;12:456-460
16. Meek JL, Fuxe K, Carlsson A. Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and ineperidine. Biochem Phannacol 1971;20:707-709
17. Butcher J. A Nobel pursuit. Lancet 2000;356:1331
18. Owens MJ. Molecular and cellular mechanisms of antidepressant dmgs. Depress Anxiety 1996:4:153-159
19. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-1322
20. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRJs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350
21. Vaishnavi SN, Nemeroff CE, Plott SJ, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. In press
22. Javors MA, Houston IF, Tekell IL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000;3:229-235
23. Harvey AT, Rudolph RL, Preskom SH. Hvidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509
24. Gilmor ML. Owens MJ, Nemeroff CE. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002;159:1702-1710
25. Anderson IM. Selective serotonin reuptake inhibitors versus tricycic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58: 19-36
26. Thase ME, Hntsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotooin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241